Engrail

Engrail Therapeutics

This company develops small-molecule therapies for patients with neurologic, neuropsychiatric and neurodevelopmental disorders such as anxiety, depression and rare diseases.

Neumora Therapeutics

This biopharmaceutical company develops medicines for patients with neuropsychiatric disorders and neurodegenerative diseases.

Noema Pharma

This company develops clinical-stage therapeutic products for patients with central nervous system disorders and orphan neurological conditions.

Draig Therapeutics

The company develops neuromodulators and receptor potentiators for patients with major depressive disorder and other neuropsychiatric conditions.

Neurosciences

This company develops precision sodium channel therapeutics to treat patients with neurological conditions such as genetic epilepsy and chronic neuropathic pain.

Exin Therapeutics

This company develops an artificial intelligence platform to discover and design neurotherapeutics targeting neural circuits for patients with neurological and neuropsychiatric disorders.

Delix

This company develops non-hallucinogenic neuroplasticity-promoting medicines to treat neuropsychiatric and neurodegenerative conditions for patients with brain disorders.

Kasvu Therapeutics

This company develops small-molecule neuroplastogen treatments for neuropsychiatric and neurodegenerative disorders, targeting patients with major depressive disorder and brain diseases.